A Phase 1 interventional study of Acalabrutinib in Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), sponsored by Acerta Pharma BV. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse — 5 open to participants now, 12 under way, 2 of them phase 3. acalabrutinib · Lymphoma, Large B-Cell, Diffuse.
Among the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 14th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 1st registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →5 of the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Brazil, Puerto Rico and 2 more countries
Ages 65–99
Universität des Saarlandes · Sites in Germany
Ages 61+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18–70
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Ruijin Hospital
Ages 18–75
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 2
First in 2014; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 72 across the 15 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca: 1 open now, 3 under way, 1 of them phase 3. Of 8 finished, 4 (50%) have results posted.
Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AstraZeneca, this one is the 10th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 1, and was the 3rd registered.
AstraZeneca’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2011.
5 of the studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
| NCT05256641Jonsson Comprehensive Cancer CenterAcalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | 2027-01-31 |
| NCT04002947National Cancer Institute (NCI)Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | 2027-10-12 |
| NCT04546620University Hospital Southampton NHS Foundation TrustAcalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among AstraZeneca’s 12 in Lymphoma, Large B-Cell, Diffuse:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To characterize the safety profile of acalabrutinib in subjects with relapsed or refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Acalabrutinib
Also known as: ACP-196
Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL.
Safety assessments included SAEs TEAEs, including AEs leading to discontinuation of study drug or dose reduction.
Time frame: SAEs collected from time of consent; TEAEs beginning after first dose and continuing through 30 days (+/- 7 days) after last dose.
Area Under the Plasma Concentration (AUC)
To Characterize the Pharmacokinetic parameter AUC of acalabrutinib
Time frame: 1 Cycle (28 days)
Maximum Observed Plasma Concentration (Cmax)
To Characterize the Pharmacokinetic parameter Cmax of acalabrutinib
Time frame: 1 Cycle (28 days)
Evaluate Pharmacodynamic (PD) Effects (Done at US Sites Only)
To evaluate the concentration pharmacodynamic effects of acalabrutinib
Time frame: 2 Cycles (1 cycle = 28 days) and at end of treatment
Evaluate Activity of Acalabrutinib as Measured by Overall Response Rate (ORR)
To evaluate the activity of acalabrutinib as measured by ORR
Time frame: From enrollment to the date of disease progression, assessed up to Cycle 48 (1 cycle is 28 days)
| Milestone | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects |
|---|---|---|
| Started | 11 | 10 |
| Enrolled | 11 | 10 |
| Received study medication | 11 | 10 |
| Discontinued study | 11 | 9 |
| Subjects continuing study medication | 0 | 1 |
| Completed | 0 | 1 |
| Not completed | 11 | 9 |
Safety assessments included SAEs TEAEs, including AEs leading to discontinuation of study drug or dose reduction.
| Participants | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects |
|---|---|---|
| Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. | 3 | 2 |
To Characterize the Pharmacokinetic parameter AUC of acalabrutinib
Results for this outcome have not been posted.
To Characterize the Pharmacokinetic parameter Cmax of acalabrutinib
Results for this outcome have not been posted.
To evaluate the concentration pharmacodynamic effects of acalabrutinib
Results for this outcome have not been posted.
To evaluate the activity of acalabrutinib as measured by ORR
Results for this outcome have not been posted.
Collected over Reported Adverse Events (AEs) include events starting on or after Day 0 and on or before Day 697. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 - Relapse Subjects | 3/11 (27.3%) | 4/11 (36.4%) | 10/11 (90.9%) |
| Cohort 2 - Refractory Subjects | 5/10 (50%) | 5/10 (50%) | 10/10 (100%) |
| Event | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects |
|---|---|---|
| Abdominal painGastrointestinal disorders | 0/11 | 2/10 |
| PyrexiaGeneral disorders | 1/11 | 1/10 |
| FatigueGeneral disorders | 0/11 | 1/10 |
| PneumoniaInfections and infestations | 0/11 | 1/10 |
| Viral infectionInfections and infestations | 0/11 | 1/10 |
| Decreased appetiteMetabolism and nutrition disorders | 0/11 | 1/10 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/11 | 1/10 |
| Skin necrosisSkin and subcutaneous tissue disorders | 0/11 | 1/10 |
| Disease progressionGeneral disorders | 1/11 | 0/10 |
| Septic shockInfections and infestations | 1/11 | 0/10 |
| Event | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 8/11 | 1/10 |
| DizzinessNervous system disorders | 5/11 | 1/10 |
| AnaemiaBlood and lymphatic system disorders | 2/11 | 4/10 |
| FatigueGeneral disorders | 4/11 | 4/10 |
| ConstipationGastrointestinal disorders | 4/11 | 0/10 |
| NauseaGastrointestinal disorders | 2/11 | 3/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/11 | 3/10 |
| HeadacheNervous system disorders | 3/11 | 2/10 |
| VomitingGastrointestinal disorders | 0/11 | 2/10 |
| Oedema peripheralGeneral disorders | 2/11 | 2/10 |
| Age, Continuous(Year) | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects | Total |
|---|---|---|---|
| Mean | 70.7 ± 9.57 | 56.9 ± 16.26 | 64.1 ± 14.66 |
| Sex: Female, Male(Participants) | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects | Total |
|---|---|---|---|
| Female | 6 | 5 | 11 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 10 | 9 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 10 | 5 | 15 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Region of Enrollment(Participants) | Cohort 1 - Relapse Subjects | Cohort 2 - Refractory Subjects | Total |
|---|---|---|---|
| United States | 9 | 6 | 15 |
| United Kingdom | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: htttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. URL:
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Aug 2014 to primary completion in Jun 2020, 70 months.
Results were first posted in Jul 2020, the month primary completion was reached.
Of 84 industry-sponsored phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 71. This study's 70 months is above that.
Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Lymphoma, Large B-Cell, Diffuse →